the effect of calorie restriction with medium fiber diet in obese and overweight type 2 diabetic patients

clinical trial of calorie restriction with medium fiber diet on serum levels of some inflammatory factors and their gene expression in obese and overweight type 2 diabetic patients with CC and TT/TC polymorphism in APOA-II and comparison of changes in these genotypes

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015071323195N1

Enrollment

Registered

2015-10-22

Start date

2015-10-12

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: non-insulin-dependent diabetes. Condition 2: obesity. Non-insulin-dependent diabetes mellitus Obesity

Interventions

During a 6-week patients will receive low-energy diet and moderate fiber (30 grams per day) including 55 to 65% carbohydrates, 20% protein and 25% fat. To get enough fiber in addition to increasing th

Lifestyle

Eligibility

Sex/Gender

All

Age

49 Years to 29 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 45-65 years; BMI more than or equal 27; type 2 diabetes who do not inject insulin Exclusion criteria: compliance of dietary recommendations less than 80%; Acute inflammatory diseases in the last 3 days before blood sampling; receiving antiinflammatory medications and multivitamin mineral supplements during the intervention

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Paraoxonase 1 enzyme. Timepoint: before and after intervention. Method of measurement: kit.;Activity of LCAT enzyme. Timepoint: before and after intervention. Method of measurement: kit.;Serum TNF-a. Timepoint: before and after intervention. Method of measurement: kit.;VCAM1, ICAM1, PTX3 gene expression. Timepoint: before and after intervention. Method of measurement: Real-Time PCR.;Paraoxonase3 enzyme. Timepoint: before and after intervention. Method of measurement: kit.;Serum NFKB. Timepoint: before and after intervention. Method of measurement: kit.;Serum ICAM1. Timepoint: before and after intervention. Method of measurement: kit.;Serum VCAM1. Timepoint: before and after intervention. Method of measurement: kit.;Serum HDL2 and HDL3. Timepoint: before and after intervention. Method of measurement: kit.	—

Measure

Time frame

Paraoxonase 1 enzyme. Timepoint: before and after intervention. Method of measurement: kit.;Activity of LCAT enzyme. Timepoint: before and after intervention. Method of measurement: kit.;Serum TNF-a. Timepoint: before and after intervention. Method of measurement: kit.;VCAM1, ICAM1, PTX3 gene expression. Timepoint: before and after intervention. Method of measurement: Real-Time PCR.;Paraoxonase3 enzyme. Timepoint: before and after intervention. Method of measurement: kit.;Serum NFKB. Timepoint: before and after intervention. Method of measurement: kit.;Serum ICAM1. Timepoint: before and after intervention. Method of measurement: kit.;Serum VCAM1. Timepoint: before and after intervention. Method of measurement: kit.;Serum HDL2 and HDL3. Timepoint: before and after intervention. Method of measurement: kit.

—

Secondary

Measure	Time frame
-. Timepoint: -. Method of measurement: -.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMasoumeh Moradi

Tehran University of Medical Sciences, School of Nutritional Science and Ditetics

moradi_ma@yahoo.com;m_moradi@razi.tums.ac.ir+98 21 4473 3292

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026